ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026

ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M

ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026